Clinical trials: Moderately Active Ulcerative Colitis

Ulcerative Colitis

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Active, not recruiting
• Age: 16 to 80 years
• Phase 3
• Injection or infusion

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis.

Trial name

NCT06052059

Testing

IV Tulisokibart, SC Tulisokibart

Where

476 sites in United States, Argentina and 43 more

Volunteers

1,109 people

Sponsor

Merck Sharp & Dohme LLC